IASLC 2021 World Conference on Lung Cancer*

Download All
September 8-14, 2021; Virtual Meeting
Review Capsule summaries and expert analysis of key studies presented at the IASLC 2021 World Conference on Lung Cancer virtual meeting.

WCLC Highlights

Capsule Summary Slidesets

In this post hoc subgroup analysis, first-line cemiplimab significantly improved PFS and numerically improved OS and ORR vs platinum-based chemotherapy in patients with locally advanced NSCLC and PD-L1 ≥50% who were ineligible for definitive concurrent chemoradiotherapy or had recurrence after concurrent chemoradiotherapy.

Released: September 16, 2021

In this updated analysis, datopotamab deruxtecan was associated with durable antitumor activity and a manageable safety profile in patients with heavily pretreated advanced NSCLC.

Released: September 16, 2021

First-line treatment with nivolumab plus ipilimumab plus chemotherapy was associated with improved systemic and intracranial outcomes in patients with advanced NSCLC, both with and without brain metastases at baseline.

Released: September 17, 2021

In this phase II study, atezolizumab plus carboplatin/pemetrexed was well tolerated and showed concordant systemic and intracranial efficacy in patients with advanced NSCLC and untreated brain metastases.

Released: September 20, 2021

In this analysis of a dose-expansion cohort from an ongoing phase I/II trial, mobocertinib was associated with clinical activity and manageable safety in patients with EGFR ex20ins–positive advanced NSCLC with disease progression after responding to or achieving stable disease on prior EGFR TKI therapy.

Released: September 23, 2021

EGFR/HER2 inhibitor DZD9008 was well tolerated with promising antitumor activity in patients with EGFR ex20ins mutation–positive advanced NSCLC with or without brain metastasis.

Released: September 20, 2021

Phase I results suggest promising clinical activity with amivantamab in unresectable or metastatic NSCLC driven by a MET exon 14 skipping mutation.

Released: September 23, 2021

Expanded analysis of cohort of patients with TRK fusion–positive lung cancer who received larotrectinib in a phase I or II basket trial suggests rapid, durable activity with larotrectinib, including in patients with CNS disease.

Released: September 15, 2021

Durvalumab plus chemotherapy significantly improved PFS vs chemotherapy alone in patients with previously untreated metastatic NSCLC.

Released: September 16, 2021

In this phase III trial, the combination of lurbinectedin plus doxorubicin was not associated with a survival benefit over standard chemotherapy in patients with relapsed SCLC.

Released: September 17, 2021

DFS benefit with adjuvant atezolizumab vs best supportive care was seen across most disease stages and prior treatments.

Released: September 15, 2021

Early data suggest that mesothelin-targeted CAR T-cell therapy with or without pembrolizumab is associated with a tolerable safety profile and clinical activity in patients with malignant pleural cancers.

Released: September 24, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Janssen Pharmaceutica NV
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue